One of the key strategies adopted by the companies in the cell & gene therapy manufacturing services market is investing in capacity expansion. This is majorly done through building new facilities or upgrading existing ones to accommodate high-demand gene and cell therapy projects. In January 2023, FUJIFILM Irvine Scientific, Inc. launched the BalanCD HEK293 Viral Feed, which is intended to enhance AAV production for gene therapy applications and viral vector-based vaccines. These launches, in addition to other strategic activities, including geographical expansion, and partnerships between firms are projected to influence positive significant market activities, maintaining healthy competition between the players. Some of the prominent players are:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?